Decentralised trials and the rare-disease infrastructure
Software-as-a-medical-device, in-vitro diagnostics, and decentralised trial infrastructure are reshaping how rare-disease therapy gets developed and delivered.
Digital diagnostics, software medical devices, and decentralised trials are quietly reshaping the infrastructure of rare-disease drug development and routine care. The category is broad - we are watching where it actually matters.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
← Back to Signals
Published by PatientSpotlight, by PanaceaIntel.